Development Diligence Obligations. AstraZeneca shall use Commercially Reasonable Efforts to apply for and obtain Regulatory Approval of the Collaboration Product in the ROW Territory, and Xxxxxxxxx shall use Commercially Reasonable Efforts to apply for and obtain Regulatory Approval of the Collaboration Product in China, in each case, as soon as reasonably practicable. AstraZeneca shall use Commercially Reasonable Efforts to Develop or procure the Development of any Diagnostic Products reasonably necessary to Commercialize the Collaboration Products and to apply for and obtain Regulatory Approval of such Diagnostic Products in the Territory as soon as reasonably practicable.
Development Diligence Obligations. During the Term, Licensee will (a) use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval of a TAK-385 Licensed Product in the Women’s Health Field in the United States [***], (b) use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval of a TAK-385 Licensed Product in the Men’s Health Field in Japan and the United States, (c) use Commercially Reasonable Efforts to [***] set forth in the TAK-385 Development Plan, (d) use Commercially Reasonable Efforts to [***], and (e) [***]. In addition, during the Term, Licensee will use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval of a TAK-448 Licensed Product in the Field in one country or jurisdiction in the Licensee Territory.
Development Diligence Obligations. On a Research Program-by-Research Program basis, following Xxxxxxx’x exercise of an Option with respect to a Research Program pursuant to Section 3.2 (Option Exercise), Xxxxxxx will use Commercially Reasonable Efforts to [***]. Xxxxxxx will have no other diligence obligations under this Agreement with respect to the Development or Regulatory Approval of any Compounds or Products.
Development Diligence Obligations. Shionogi shall use Commercially Reasonable Efforts to Develop Products in each Specified Territory (it being understood that, for the avoidance of doubt, a breach of the foregoing obligation in any country within a Specified Territory shall not be considered a breach or violation of this Section 4.1.4 if such breach is not material to such Specified Territory taken as a whole). Without limiting Egalet’s obligations under Section 4.1.1, each Party shall use Commercially Reasonable Efforts to implement and conduct the Development assigned to such Party under this Agreement, and to cooperate with and provide reasonable support to the other Party in such other Party’s conduct of Development under this Agreement.
Development Diligence Obligations. If Biogen has commenced an IND-Enabling Study for a Development Candidate directed to a Collaboration Target in the United States or one Major European Market, then Biogen, itself or through its Affiliates, Sublicensees, or Subcontractors, will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least [***] directed to such Collaboration Target in the United States or [***] Major European Market. Biogen will have no other diligence obligations under this Agreement with respect to the Development or Regulatory Approval of any Development Candidates or Products.
Development Diligence Obligations. Kiniksa shall use Commercially Reasonable Efforts to Develop the Product in the Kiniksa Field in the Territory. Without limiting the foregoing, Kiniksa shall use Commercially Reasonable Efforts to undertake and perform the Development activities set forth in the then-current Development Plan for the Product in the Kiniksa Field in a timely manner. Kiniksa shall conduct all such activities in compliance with Applicable Laws.
Development Diligence Obligations. Subject to the terms of this Agreement, including Section 5.4.2 (Pivotal Trial for the HCC Indication), CStone will be responsible and will use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for (which will be on Blueprint’s behalf until [***]) each Collaboration Product with respect to which the JSC has approved a Territory-Specific Development Plan or, to the extent CStone is allocated Development responsibilities thereunder, Global Development Plan in the Field in the Territory. Without limiting the generality of the foregoing, CStone will use Commercially Reasonable Efforts to (a) perform the activities set forth in, and Develop each Collaboration Product in accordance with, the Territory-Specific Development Plan for such Collaboration Product and achieve the objectives set forth therein, and (b) subject to Section 3.7.2 (Final Decision-Making Authority), conduct the tasks assigned to CStone in each Global Development Plan for such Collaboration Product (including as set forth in such Global Development Plan), implement Global Clinical Trials for such Collaboration Product in the Territory (including engagement of principal investigators and support of the initiation of sites for Global Clinical Trials in the Territory that are specified in such Global Development Plan), and achieve the objectives set forth therein to support the global Development and registration of each applicable Collaboration Product.
Development Diligence Obligations. BMS will use [**] to Develop and obtain Regulatory Approval (including Pricing Approval, if applicable) for [**] Licensed Product in at least one Indication in the Field in each of [**].
Development Diligence Obligations. Except as provided in this Agreement with respect to the Ongoing CS1001 ENKTL Trial and the Ongoing CS1003 HCC Trial, EQRx will be responsible for and will use [***] to Develop and obtain Regulatory Approval (and, where applicable, Pricing and Reimbursement Approval) for (a) at least one Licensed Product that contains CS1001, and (b) at least one Licensed Product that contains CS1003, in both cases ((a) and (b)), in the Field in each of the United States, Japan, and at least two Major European Countries, at its cost and expense. EQRx will perform all obligations under this Agreement, including under a Global Development Plan, in a timely, professional manner and in compliance with all applicable laws, including as applicable GLP, GCP, and cGMP.
Development Diligence Obligations. Evelo will use Commercially Reasonable Efforts to Develop EDP1815 in order to obtain approval of a BLA for EDP1815 in at least one of the United States of America, the United Kingdom of Great Britain and Northern Ireland, France, Germany, Spain, Italy, China, and Japan. Each Party will use Commercially Reasonable Efforts to perform all activities allocated to it in the Development Plan and will not take any action that conflicts with the Development Plan. ALJ will not perform any Development activities for the Products other than in accordance with the Development Plan.
